#Sweden #Stockholm #Eisai #Leqembi #BioArctic

Leqembi® Achieves Impressive Sales in Q4 2025

In a remarkable financial announcement, BioArctic AB's partner, Eisai, revealed that Leqembi® generated sales totaling an impressive 20.7 billion yen in the fourth quarter of 2025. This surge in revenue marks a significant milestone in the collaboration between these two companies, which has been dedicated to the advancement of Alzheimer's disease treatments.

The reported figures from Eisai not only highlight the success of Leqembi but also result in a substantial royalty payment to BioArctic, amounting to approximately SEK 127 million. This figure represents a notable increase of around 31% compared to the same quarter last year, reflecting both the growing market momentum for Leqembi and the favorable foreign exchange rates. If the exchange rates had remained steady, the royalty increase would have been closer to 50%, underscoring the drug's rising demand in the global market.

Eisai plans to release its complete results for the third quarter of FY 2025, covering the period from October to December 2025, on February 9, 2026. Furthermore, BioArctic is set to present its full-year financial report for 2025 on February 18, 2026, at 08:00 CET, which will provide further insights into the performance and future outlook of Leqembi.

About Leqembi®

Leqembi, known scientifically as lecanemab, is a monoclonal antibody targeting amyloid-beta, which is implicated in the pathology of Alzheimer's disease. This breakthrough treatment has gained approvals in 53 countries and is under regulatory review in six additional locations. Following an initial treatment phase conducted every two weeks over 18 months, patients can switch to a less frequent maintenance infusion, available every four weeks in several countries including the U.S. and the UK.

In a significant regulatory advancement, Leqembi Iqlik™, a version of the drug allowing for subcutaneous administration using an autoinjector, has been approved in the U.S. for early Alzheimer's disease maintenance treatment. Eisai recently submitted a new drug application for a similar subcutaneous formulation in Japan, with expected approval timelines set for May 24, 2026.

Continuing Research and Development

The development trajectory for Leqembi has been supported by several clinical trials, including the AHEAD 3-45 study, focused on patients with preclinical Alzheimer's disease. This long-term study aims to investigate the potential benefits of lecanemab in early intervention, thus helping reduce the progression of cognitive impairment.

Moreover, the Tau NexGen clinical study targeting Dominantly Inherited Alzheimer's disease (DIAD) is set to further explore the efficacy of lecanemab in this specialized population.

The collaboration between BioArctic and Eisai has been pivotal in developing innovative solutions for neurodegenerative conditions since 2005. Their partnership has strengthened over the years with various agreements focused on commercialization and research, enabling BioArctic to concentrate on its broader pharmaceutical portfolio without incurring development costs.

Conclusion

With the promising performance of Leqembi in the latest financial quarter and ongoing clinical investigations, BioArctic and Eisai's partnership appears well-positioned to make significant strides in Alzheimer's treatment. As they continue to harness innovative research capabilities, the outlook for both companies and their development pipeline remains bright, offering hope to patients and families affected by this debilitating disease.